Clinical Trials › NCT03958877
Active, Not RecruitingPhase 3
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Sponsored by Biogen
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 152
Target enrollment
3
U.S. states
Oct 2019
Start date
May 2027
Expected completion
Interventions / Treatments
BIIB017 (peginterferon beta-1a)Interferon beta type 1a
Conditions studied
Multiple Sclerosis, Relapsing-Remitting
Where this trial is running (3 sites)
Participating MS centers on MS Buddy (2)
UC San Diego Health MS Program
La Jolla, CA
La Jolla, CA
UNC Department of Neurology MS/Neuroimmunology Division
Chapel Hill, NC
Chapel Hill, NC
MS centers in California
Compare treatment centers near a trial site by center type, providers and trials.
View California centersMore Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.